Targeting the MET oncogene in cancer and metastases

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Invasive growth is a critical biological process in development and regeneration, frequently hijacked by cancer cells.
• The MET oncogene plays a significant role in promoting invasive growth in human cancers, primarily via overexpression driven by the tumor microenvironment.
• MET activation provides neoplastic cells with a survival advantage, contributing to tumor progression and resistance to therapies, with some tumors exhibiting MET addiction.

Purpose of the Study:

• To review the molecular basis and rationale for targeting MET signaling in cancer and metastasis.
• To discuss the current landscape of MET inhibitors, including ongoing clinical trials.
• To outline strategies for selecting patients who are most likely to benefit from MET-targeted therapies.

Main Methods:

• Discussion of the molecular mechanisms underlying MET-driven invasive growth.
• Review of preclinical and clinical data on MET inhibitors.
• Analysis of patient selection strategies based on molecular alterations and response predictors.

Main Results:

• Comprehensive overview of the state-of-the-art in anti-MET targeted approaches.
• Detailed explanation of the molecular basis for MET inhibition.
• Identification of strategies for selecting patients eligible for MET inhibitor treatment.

Conclusions:

• MET is a promising therapeutic target in cancer due to its multifaceted roles.
• Understanding mechanisms of sensitization and resistance to MET inhibitors is crucial.
• Tailored therapies and precise patient selection are priorities for maximizing clinical benefit from MET-targeted treatments.